Trial Profile
Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Rintatolimod (Primary) ; Aspirin; Interferon alpha-2b
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- 23 Feb 2024 Planned End Date changed from 29 Nov 2024 to 29 May 2024.
- 23 Feb 2024 Planned primary completion date changed from 29 Nov 2023 to 29 May 2024.
- 27 Jan 2024 Interim Results (n=11) assessing safety and efficacy of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy presented at the 2024 Genitourinary Cancers Symposium